➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Dow
AstraZeneca
Baxter
McKesson

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Rogaratinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Rogaratinib?

Rogaratinib is an investigational drug.

There have been 11 clinical trials for Rogaratinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 31st 2018.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Breast Neoplasms. The leading clinical trial sponsors are Bayer, Pfizer, and Apices Soluciones S.L.

There are two US patents protecting this investigational drug and sixty-five international patents.

Recent Clinical Trials for Rogaratinib
TitleSponsorPhase
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)National Cancer Institute (NCI)Phase 2
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.Apices Soluciones S.L.Phase 1
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.BayerPhase 1

See all Rogaratinib clinical trials

Clinical Trial Summary for Rogaratinib

Top disease conditions for Rogaratinib
Top clinical trial sponsors for Rogaratinib

See all Rogaratinib clinical trials

US Patents for Rogaratinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Rogaratinib   Start Trial Substituted 2,3-dihydroimidazo[1,2-C]quinazoline-containing combinations BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)   Start Trial
Rogaratinib   Start Trial Disubstituted benzothienyl-pyrrolotriazines and uses thereof BAYER INTELLECTUAL PROPERTY GmbH (Monheim, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Rogaratinib

Drugname Country Document Number Estimated Expiration Related US Patent
Rogaratinib Australia AU2016231259 2035-03-09   Start Trial
Rogaratinib Brazil BR112017019188 2035-03-09   Start Trial
Rogaratinib Canada CA2978830 2035-03-09   Start Trial
Rogaratinib China CN107864625 2035-03-09   Start Trial
Rogaratinib Eurasian Patent Organization EA201791974 2035-03-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Dow
AstraZeneca
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.